Price Chart

Profile

Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities unique to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases. Its drug candidates include, UBX1325 is being developed for age-related diseases of the eye, including diabetic macular edema, or DME, UBX2089, which is a circulating hormone primarily produced in the kidneys and choroid plexus of the brain, which is being researched for multiple neurology indications, and UBX2050.
URL https://www.unitybiotechnology.com
Investor Relations URL https://ir.unitybiotechnology.com/
HQ State/Province California
Sector Health Care
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release Apr. 15, 2025 (est.)
Last Earnings Release Nov. 04, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Profile

Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities unique to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases. Its drug candidates include, UBX1325 is being developed for age-related diseases of the eye, including diabetic macular edema, or DME, UBX2089, which is a circulating hormone primarily produced in the kidneys and choroid plexus of the brain, which is being researched for multiple neurology indications, and UBX2050.
URL https://www.unitybiotechnology.com
Investor Relations URL https://ir.unitybiotechnology.com/
HQ State/Province California
Sector Health Care
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release Apr. 15, 2025 (est.)
Last Earnings Release Nov. 04, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A